Allergan AGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Ultimate Stock-Pickers' Top 10 Buys and Sells


      Tue, 3 Mar 2015

      WellsFargo WFC 3 Medium Narrow 54.79 1.05 282,581 5 Allergan AGN 3 Medium Wide 232.74 1.03 70,358 3 Occidental ..... acquisitions announced during the period (with wide-moat Allergan AGN fitting the bill this time around). With regards to

    2. Compelling Financial Benefit in Valeant's Latest Buy


      Fri, 27 Feb 2015

      year-plus record of success to be encouraging. He has demonstrated a willingness and ability to walk away from a target ( Allergan , Cephalon, and so on) and avoids bidding wars whenever possible. He lacks a scientific background or experience in research

    3. UPDATE 3-Actavis to take Allergan name, reflecting brand-drug focus


      Wed, 18 Feb 2015

      Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected

    4. Actavis Reports Strong Fourth Quarter Heading Into Allergan Acquisition


      Wed, 18 Feb 2015

      in 2015 as the planned acquisition of Allergan remains on track for early this year despite ..... billion in revenue for 2015 before the Allergan deal. We continue to think Actavis earns ..... economic moat thanks to the inheritance of Allergan ’s defensible branded products and pipeline

    5. Undervalued Valeant's Unique Strategy Is Underappreciated

      Video Reports

      Wed, 18 Feb 2015

      stewardship rating. They have shown they are willing to walk away when deal prices get too high, which we saw recently with Allergan ( AGN ), as well as a number of other times over the last six years. They have also shown a willingness to buy back their

      Allergan AGN found at 0:56

      away when deal prices get too high, which we saw recently with Allergan ( AGN ), as well as a number of other times over the last six years. They have also shown a willingness to buy back
    6. Ultimate Stock-Pickers' Top 10 High-Conviction Purchases


      Wed, 18 Feb 2015

      a mutually agreed upon acquisition of Allergan , a stock owned in the portfolio since ..... operational synergies and, combined with Allergan , will have strong brands across multiple ..... pharmaceutical company that agreed to buy Allergan , is the only new portfolio company in

    7. What to Watch in the Day Ahead - Wednesday, Feb. 18


      Tue, 17 Feb 2015

      register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Actavis Plc, which will buy Botox maker Allergan next month, is expected to announce a higher fourth-quarter profit. Earnings are expected to have increased due to acquisitions

    8. From Barron’s, February 9, 2015 (Part 2)


      Sat, 7 Feb 2015

      dividends and buybacks. This can go on for only so long. There are some companies that have good organic growth potential, AET, AGN , ORLY . This may finally be the year for small stocks – they don’t have headwind from strong dollar as most of them are

    9. Allergan ’s Results Support Strong Growth Outlook for Combination With Actavis


      Wed, 4 Feb 2015

      Allergan posted fourth-quarter results that slightly ..... view that Actavis has much to gain from Allergan 's growth opportunities and competitive ..... support our standalone projections for Allergan of double-digit revenue growth over

    10. How the Actavis deal upended Allergan No. 2's CEO ambitions


      Tue, 3 Feb 2015

      NEW YORK (Reuters) - For two decades, Allergan Inc president Doug Ingram labored to transform the Botox-maker from a sleepy eye care upstart to a global aesthetics giant. He was

    « Prev12345Next »
    Content Partners